Glimeto-M1 Tablets

Composition

• Metformin Hydrochloride (Prolonged Release) – 500 mg
• Glimepiride – 1 mg

---

Mechanism of Action

Metformin Hydrochloride (Prolonged Release) works by reducing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The prolonged-release formulation ensures sustained drug release, leading to better glycemic control and improved gastrointestinal tolerability.

Glimepiride, a sulfonylurea, stimulates insulin secretion from pancreatic beta cells, thereby helping in lowering blood glucose levels effectively.

---

Key Benefits

• Dual mechanism for effective blood glucose control
• Helps reduce fasting and postprandial glucose levels
• Sustained release for prolonged action
• Supports reduction in HbA1c levels
• Improves insulin sensitivity
• Convenient once-daily dosing (as prescribed)

---

Indications

• Type 2 Diabetes Mellitus
• Patients inadequately controlled with monotherapy
• Combination therapy for improved glycemic management

---

Dosage & Administration

• To be taken as directed by the physician
• Usually taken with meals to reduce gastrointestinal discomfort
• Tablets should be swallowed whole and not crushed or chewed

---

Precautions

• Risk of hypoglycemia due to sulfonylurea component
• Use with caution in renal or hepatic impairment
• Regular monitoring of blood glucose is recommended
• Avoid excessive alcohol intake

---

Contraindications

• Type 1 Diabetes Mellitus
• Diabetic ketoacidosis
• Severe renal or hepatic impairment
• Known hypersensitivity to any component

---

Storage

• Store in a cool and dry place below 25°C
• Protect from light and moisture
• Keep out of reach of children

---

Packaging

• 10 x 15 Tablets